This is an aggregated industry headline. Read the full story at Drug Channels →
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx's Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
By Adam J. Fein, Ph.D.Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque: Why Optum Rx Is Accelerating Its Transparency Strategy The Most Important 340B Paper You'll Ever Read Blue Shield of Cali
By Drug Channels
· May 27, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. …
The WeekFierceBiotech ↗
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to foc…
The WeekBriefing
Takeda won FDA approval for Orzeyful in adults with narcolepsy type 1. The decision introduces the first appro…